Reduced intensity treatment in early-stage Hodgkin’s lymphoma
Prathima Prodduturi, James O ArmitageUniversity of Nebraska Medical Center, Omaha, NE, USAAbstract: Early-stage Hodgkin’s lymphoma which includes patients with Ann Arbor stages I or II, accounts for more than 50% of all cases of the illness and is curable in a high proportion of patien...
Main Authors: | Armitage JO, Prodduturi P |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2011-11-01
|
Series: | Blood and Lymphatic Cancer : Targets and Therapy |
Online Access: | http://www.dovepress.com/reduced-intensity-treatment-in-early-stage-hodgkinrsquos-lymphoma-a8737 |
Similar Items
-
Bendamustine in the treatment of non-Hodgkin’s lymphomas
by: Fredrick Hagemeister, et al.
Published: (2009-12-01) -
Rituximab in the treatment of non-Hodgkin’s lymphoma
by: Beate Hauptrock, et al.
Published: (2008-09-01) -
Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma
by: Rudolf Weide
Published: (2008-09-01) -
mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report
by: Provencio M., et al.
Published: (2011-11-01) -
Update on treatment of follicular non-Hodgkin’s lymphoma: focus on potential of bortezomib
by: Brander DM, et al.
Published: (2012-03-01)